Works by Tolcher, Anthony

Results: 57
    1
    2
    3
    4

    A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.

    Published in:
    Oncologist, 2018, v. 23, n. 6, p. 658, doi. 10.1634/theoncologist.2017-0325
    By:
    • Tolcher, Anthony;
    • Flaherty, Keith;
    • Shapiro, Geoffrey I.;
    • Berlin, Jordan;
    • Witzig, Thomas;
    • Habermann, Thomas;
    • Bullock, Andrea;
    • Rock, Edwin;
    • Elekes, Agnes;
    • Lin, Chester;
    • Kostic, Dusan;
    • Ohi, Naoto;
    • Rasco, Drew;
    • Papadopoulos, Kyriakos P.;
    • Patnaik, Amita;
    • Smith, Lon;
    • Cote, Gregory M.
    Publication type:
    Article
    5
    6

    Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

    Published in:
    Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 3, doi. 10.1186/1756-8722-7-1
    By:
    • Rhoda Molife, L.;
    • Li Yan;
    • Vitfell-Rasmussen, Joanna;
    • Zernhelt, Adriane M.;
    • Sullivan, Daniel M.;
    • Cassier, Philippe A.;
    • Eric Chen;
    • Biondo, Andrea;
    • Tetteh, Ernestina;
    • Siu, Lillian L.;
    • Patnaik, Amita;
    • Papadopoulos, Kyriakos P.;
    • De Bono, Johann S.;
    • Tolcher, Anthony W.;
    • Minton, Susan
    Publication type:
    Article
    7
    8

    Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.

    Published in:
    2020
    By:
    • Tolcher, Anthony W.;
    • Kurzrock, Razelle;
    • Valero, Vincente;
    • Gonzalez, Rene;
    • Heist, Rebecca S.;
    • Tan, Antoinette R.;
    • Means-Powell, Julie;
    • Werner, Theresa L.;
    • Becerra, Carlos;
    • Wang, Chenxi;
    • Leonowens, Cathrine;
    • Kalyana-Sundaram, Shanker;
    • Kleha, Joseph F.;
    • Gauvin, Jennifer;
    • D'Amelio, Anthony M.;
    • Ellis, Catherine;
    • Ibrahim, Nageatte;
    • Yan, Li;
    • D'Amelio, Anthony M Jr
    Publication type:
    journal article
    9

    Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

    Published in:
    2017
    By:
    • Infante, Jeffrey;
    • Patnaik, Amita;
    • Verschraegen, Claire;
    • Olszanski, Anthony;
    • Shaheen, Montaser;
    • Burris, Howard;
    • Tolcher, Anthony;
    • Papadopoulos, Kyriakos;
    • Beeram, Muralidhar;
    • Hynes, Scott;
    • Leohr, Jennifer;
    • Lin, Aimee;
    • Li, Lily;
    • McGlothlin, Anna;
    • Farrington, Daphne;
    • Westin, Eric;
    • Cohen, Roger;
    • Infante, Jeffrey R;
    • Verschraegen, Claire F;
    • Olszanski, Anthony J
    Publication type:
    journal article
    10
    11
    12
    13
    14

    Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 1, p. 77, doi. 10.1007/s00280-014-2479-8
    By:
    • Mahalingam, Devalingam;
    • Malik, Laeeq;
    • Beeram, Muralidhar;
    • Rodon, Jordi;
    • Sankhala, Kamalesh;
    • Mita, Alain;
    • Benjamin, Daniel;
    • Ketchum, Norma;
    • Michalek, Joel;
    • Tolcher, Anthony;
    • Wright, John;
    • Sarantopoulos, John
    Publication type:
    Article
    15
    16
    17
    18

    A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 4, p. 1041, doi. 10.1007/s00280-013-2099-8
    By:
    • Sandhu, Shahneen;
    • Papadopoulos, Kyri;
    • Fong, Peter;
    • Patnaik, Amita;
    • Messiou, Christina;
    • Olmos, David;
    • Wang, George;
    • Tromp, Brenda;
    • Puchalski, Thomas;
    • Balkwill, Frances;
    • Berns, Birge;
    • Seetharam, Shobha;
    • Bono, Johann;
    • Tolcher, Anthony
    Publication type:
    Article
    19
    20

    A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 4, p. 567, doi. 10.1007/s00280-012-1942-7
    By:
    • Lush, Richard;
    • Patnaik, Amita;
    • Sullivan, Daniel;
    • Papadopoulos, Kyriakos;
    • Trucksis, Michele;
    • McCrea, Jacqueline;
    • Cerchio, Kristine;
    • Li, Xiaodong;
    • Stroh, Mark;
    • Selverian, Diana;
    • Orford, Keith;
    • Ebbinghaus, Scot;
    • Agrawal, Nancy;
    • Iwamoto, Marian;
    • Wagner, John;
    • Tolcher, Anthony
    Publication type:
    Article
    21
    22
    23
    24
    25

    Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 167, doi. 10.1007/s00280-009-1020-y
    By:
    • Chia-Chi Lin;
    • Beeram, Muralidhar;
    • Rowinsky, Eric K.;
    • Takimoto, Chris H.;
    • Ng, Chee M.;
    • Geyer Jr., Charles E.;
    • Denis, Louis J.;
    • De Bono, Johann S.;
    • Hao, Desiree;
    • Tolcher, Anthony W.;
    • Rha, Sun-Young;
    • Jolivet, Jacques;
    • Patnaik, Amita
    Publication type:
    Article
    26

    Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x
    By:
    • Chia-Chi Lin;
    • Calvo, Emiliano;
    • Papadopoulos, Kyriakos P.;
    • Patnaik, Amita;
    • Sarantopoulos, John;
    • Mita, Alain C.;
    • Preston, Glenn G.;
    • Mita, Monica M.;
    • Rodon, Jordi;
    • Mays, Theresa;
    • I.-Tien Yeh;
    • O'Rourke, Pat;
    • Takimoto, Chris H.;
    • Dancey, Janet E.;
    • Chen, Helen;
    • Tolcher, Anthony W.
    Publication type:
    Article
    27
    28
    29
    30

    Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors.

    Published in:
    2025
    By:
    • Shimizu, Toshio;
    • Powderly, John;
    • Abdul Razak, Albiruni;
    • LoRusso, Patricia;
    • Miller, Kathy D.;
    • Kao, Steven;
    • Kongpachith, Sarah;
    • Tribouley, Catherine;
    • Graham, Michelle;
    • Stoll, Brian;
    • Patel, Maulik;
    • Sahtout, Mohammad;
    • Blaney, Martha;
    • Leibman, Rachel;
    • Golan, Talia;
    • Tolcher, Anthony
    Publication type:
    Correction Notice
    31

    First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors.

    Published in:
    Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2024.1376551
    By:
    • Shimizu, Toshio;
    • Powderly, John;
    • Abdul Razak, Albiruni;
    • LoRusso, Patricia;
    • Miller, Kathy D.;
    • Kao, Steven;
    • Kongpachith, Sarah;
    • Tribouley, Catherine;
    • Graham, Michelle;
    • Stoll, Brian;
    • Patel, Maulik;
    • Sahtout, Mohammad;
    • Blaney, Martha;
    • Leibman, Rachel;
    • Golan, Talia;
    • Tolcher, Anthony
    Publication type:
    Article
    32

    First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors.

    Published in:
    Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1376551
    By:
    • Shimizu, Toshio;
    • Powderly, John;
    • Abdul Razak, Albiruni;
    • LoRusso, Patricia;
    • Miller, Kathy D.;
    • Kao, Steven;
    • Kongpachith, Sarah;
    • Tribouley, Catherine;
    • Graham, Michelle;
    • Stoll, Brian;
    • Patel, Maulik;
    • Sahtout, Mohammad;
    • Blaney, Martha;
    • Leibman, Rachel;
    • Golan, Talia;
    • Tolcher, Anthony
    Publication type:
    Article
    33
    34
    35
    36
    37
    38

    First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 3, p. 586, doi. 10.1007/s10637-022-01217-7
    By:
    • Berlin, Jordan;
    • Tolcher, Anthony W.;
    • Ding, Cliff;
    • Whisenant, Jennifer G.;
    • Horak, Ivan D.;
    • Wood, Debra L.;
    • Nadler, Paul I.;
    • Hansen, Ulla Holm;
    • Lantto, Johan;
    • Skartved, Niels Jørgen Ø.;
    • Pedersen, Mikkel W.;
    • Patnaik, Amita
    Publication type:
    Article
    39

    A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 5, p. 1483, doi. 10.1007/s10637-020-00908-3
    By:
    • Cleary, James M.;
    • Calvo, Emiliano;
    • Moreno, Victor;
    • Juric, Dejan;
    • Shapiro, Geoffrey I.;
    • Vanderwal, Carol Ann;
    • Hu, Beibei;
    • Gifford, Maryella;
    • Barch, David;
    • Roberts-Rapp, Lisa;
    • Ansell, Peter J.;
    • Xiong, Hao;
    • Ocampo, Christopher;
    • Tolcher, Anthony W.
    Publication type:
    Article
    40
    41
    42
    43
    44
    45
    46
    47
    48

    Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

    Published in:
    2018
    By:
    • Goss, Glenwood D.;
    • Vokes, Everett E.;
    • Gordon, Michael S.;
    • Gandhi, Leena;
    • Papadopoulos, Kyriakos P.;
    • Rasco, Drew W.;
    • Fischer, JuDee S.;
    • Chu, Katharine L.;
    • Ames, William W.;
    • Mittapalli, Rajendar K.;
    • Lee, Ho‐Jin;
    • Zeng, Jiewei;
    • Roberts‐Rapp, Lisa A.;
    • Loberg, Lise I.;
    • Ansell, Peter J.;
    • Reilly, Edward B.;
    • Ocampo, Christopher J.;
    • Holen, Kyle D.;
    • Tolcher, Anthony W.;
    • Lee, Ho-Jin
    Publication type:
    journal article
    49
    50